EpiPen maker Mylan to restructure and cut its workforce

(Reuters) - Generic drugmaker Mylan NV , which has been under fire for its price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it would restructure and expected to cut less than 10 percent of its global workforce.